The estimated Net Worth of Stephen Hoge is at least $179 million dollars as of 30 August 2024. Stephen Hoge owns over 652 units of Moderna Inc stock worth over $114,758,373 and over the last 6 years he sold MRNA stock worth over $59,286,502. In addition, he makes $5,001,210 as President at Moderna Inc.
Stephen has made over 136 trades of the Moderna Inc stock since 2020, according to the Form 4 filled with the SEC. Most recently he exercised 652 units of MRNA stock worth $51,841 on 30 August 2024.
The largest trade he's ever made was selling 45,000 units of Moderna Inc stock on 27 December 2023 worth over $4,500,450. On average, Stephen trades about 12,455 units every 12 days since 2018. As of 30 August 2024 he still owns at least 1,443,320 units of Moderna Inc stock.
You can see the complete history of Stephen Hoge stock trades at the bottom of the page.
Dr. Stephen Hoge M.D. serves as President of the Company. From 2010 to 2012, Dr. Hoge was a Partner at McKinsey & Company and a leader in the firm’s healthcare practice. From 2005 to 2010, he served in roles of increasing responsibility at McKinsey & Company. From 2004 to 2005, Dr. Hoge was a resident physician at New York University/Bellevue Hospital. Dr. Hoge has served on the board of directors of Axcella Health, Inc. (Nasdaq: AXLA). He received an M.D. from the University of California, San Francisco and a B.A. in neuroscience from Amherst College.
As the President of Moderna Inc, the total compensation of Stephen Hoge at Moderna Inc is $5,001,210. There are 1 executives at Moderna Inc getting paid more, with Stephane Bancel having the highest compensation of $8,948,210.
Stephen's mailing address filed with the SEC is C/O MODERNA, INC., 325 BINNEY STREET, CAMBRIDGE, MA, 02142.
Over the last 6 years, insiders at Moderna Inc have traded over $2,713,086,305 worth of Moderna Inc stock and bought 52,631 units worth $999,989 . The most active insiders traders include Noubar Afeyan, David M. Rubenstein et Stephane Bancel. On average, Moderna Inc executives and independent directors trade stock every 2 days with the average trade being worth of $2,841,687. The most recent stock trade was executed by Shannon Thyme Klinger on 6 September 2024, trading 1,139 units of MRNA stock currently worth $90,562.
moderna is pioneering messenger rna therapeutics™, an entirely new in vivo drug modality that produces human proteins or antibodies inside patient cells, which are in turn active intracellularly or secreted. this breakthrough platform addresses currently undruggable targets, and offers a superior alternative to existing drug modalities for a wide range of disease conditions. moderna has developed a broad intellectual property estate including more than 200 patent applications with more than 10,000 claims ranging from novel nucleotide chemistries to specific drug compositions. the company plans to develop and commercialize its innovative mrna drugs—initially for rare diseases and oncology—while partnering drug candidates in other therapeutics areas in order to rapidly deliver this innovation to patients. based in cambridge, massachusetts, moderna is privately held and was founded in 2010 by flagship venturelabs in association with leading scientists from boston children’s hospital a
Moderna Inc executives and other stock owners filed with the SEC include: